TruSight Oncology 500 Portfolio

Enable Comprehensive Genomic Profiling

Assess all key biomarkers in guidelines, as well as clinical trials, increasing the chances of finding a positive biomarker for every sample. Including all key genomic variants, plus the immuno-oncology biomarkers MSI and TMB (emerging), our assays enable a lab to consolidate several independent assays and workflows into a single one, at the same time saving sample, time, and money.

Implement Assays In-house

Implement the assay in-house, to better serve your local community, maintain control of sample and data, and become an active part of the molecular tumor board. With content including current and emerging biomarkers, plus an IVD roadmap in partnership with several pharmaceutical companies, these assays are made to stay in a lab for the long run.

"Integrated, Flexible, and Scalable Workflow

Assess all biomarkers in a single, integrated, 4-5 day workflow using the DRAGEN Bio-IT platform and PierianDx software to seamlessly output a final interpretation report. Benefit from the portfolio's flexibility with assays for either solid or liquid biopsy samples, automation-friendly options, and scalable sample batch sizes.

Achieve Reliable Results

Achieve reliable results with a family of assays with 99.999% analytical specificity and >95% analytical sensitivity, due to robust hybrid-capture chemistry, SBS sequencing, and sophisticated bioinformatics.